How to manage antiplatelet therapy for stenting in a patient requiring oral anticoagulants

Current Treatment Options in Cardiovascular Medicine

Volumn 15, Issue 1, 2013, Pages 11-20

  Faxon, David P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiplatelet agents; Oral anticoagulants; Stent; Triple therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BARE METAL STENT; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COMBINATION CHEMOTHERAPY; CORONARY STENT; DRUG ELUTING STENT; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRACARDIAC THROMBOSIS; LUNG EMBOLISM; MONOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STENT THROMBOSIS; TREATMENT DURATION;

EID: 84873085336     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0222-5     Document Type: Review

References (39)

1. Faxon DP, Eikelboom JW, Berger PB, Holmes Jr DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv. 2011;4:522-34. A comprehensive review of the risks and benefits of antiplatelet and anticoagulant therapy with concensus recommendations.
2. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marin F. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary - a consensus document of the european society of cardiology working group on thrombosis, endorsed by the european heart rhythm association (ehra) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010;31:1311-8. The European concensus document on the use of antithrombotic therapy for patients with atrial fibrillation undergon coronary stenting.
3. Rubboli A, Verheugt FW. Antithrombotic treatment for patients on oral anticoagulation undergoing coronary stenting: a review of the available evidence and practical suggestions for the clinician. Int J Cardiol. 2008;123:234-9.
4. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marin F. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemostasis. 2010;103:13-28.
5. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, Madsen JK, Hansen PR, Køber L, Torp-Pedersen C. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin k antagonists in denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-74.
6. Cheng A, Nazarian S, Brinker JA, Tompkins C, Spragg DD, Leng CT, Halperin H, Tandri H, Sinha SK, Marine JE, Calkins H, Tomaselli GF, Berger RD, Henrikson CA. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. Hear Rhythm. 2011;8:536-40.
7. Kiviniemi T, Karjalainen P, Pietila M, Ylitalo A, Niemela M, Vikman S, Puurunen M, Biancari F, Airaksinen KE. Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2012;110:30-5.
8. Lahtela H, Rubboli A, Schlitt A, Karjalainen PP, Niemela M, Vikman S, Puurunen M, Weber M, Valencia J, Biancari F, Lip GY, Airaksinen KE. Heparin bridging vs. Uninterrupted oral anticoagulation in patients with atrial fibrillation undergoing coronary artery stenting. Results from the afcas registry. Circ J: Off J Jpn Circ Soc. 2012;76:1363-8.
9. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin k antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126:1630-9. A meta-analysis suggesting that heparin bridging increases bleeding without a reduction in thromboembolic rates.
10. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 accf/aha/scai guideline for percutaneous coronary intervention: a report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation. 2011;124:e574-651.
11. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur Heart J. 2010;31:2501-55.
12. Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4:191-7. A study demonstrating that nonaccess bleeding was the predominant cause of bleeding and increased risk by four-fold.
13. Rao SV OGK, Pieper KS, Granger CB, Newby K, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA. Impact of bleeding severity on clinical outcomes amoung patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200-6.
14. Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, Budaj A, Niemela M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner CD, Chrolavicius S, Mehta SR. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (rival): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409-20.
15. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G, Summaria F, Patrizi R, Borghi A, Di Russo C, Moretti C, Agostoni P, Loschiavo P, Lioy E, Sheiban I, Sangiorgi G. Radial versus femoral randomized investigation in st-segment elevation acute coronary syndrome: The rifle-steacs (radial versus femoral randomized investigation in ST-elevation acute coronary syndrome) study. J Am Coll Cardiol. 2012 (epub ahead of print).
16. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-92. A large population study from California showing a significant reduction in thromboembolic events and mortality but a small increase in intracranial hemorrhage with warfarin in patients with atrial fibrillation.
17. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J. 2012;33:1500-10.
18. Coppens M, Eikelboom JW, Hart RG, Yusuf S, Lip GY, Dorian P, Shestakovska O, Connolly SJ. The cha2ds2-vasc score identifies those patients with atrial fibrillation and a chads2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J. 2012 (epub ahead of print).
19. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith Jr SC, Priori SG. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2011;123:e269-367.
20. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (active w): a randomised controlled trial. Lancet. 2006;367:1903-12.
21. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009;361:1139-51.
22. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011;365:883-91.
23. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011;365:981-92.
24. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: esc working group on thrombosis-task force on anticoagulants in heart disease position paper. J Am Coll Cardiol. 2012;59:1413-25. An excellent review of the new oral anticoagulants and their potential role in the future.
25. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabate M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-402.
26. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (last) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-92.
27. Faxon DP. Very late stent thrombosis and late target lesion revascularization: no end in sight. Circulation. 2012;125:562-4.
28. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-30.
29. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556-66.
30. Lip GY. Implications of the cha(2)ds(2)-vasc and has-bled scores for thromboprophylaxis in atrial fibrillation. Am J Med. 2011;124:111-4.
31. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the has-bled (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile inr, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol. 2011;57:173-80.
32. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Kober L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185-93. A large observational study from Denmark that showed that a single antiplatelet agent and an oral anticoagulant has signficantly lower bleeding than triple therapy with equal efficacy.
33. Gao F, Zhou YJ, Wang ZJ, Yang SW, Nie B, Liu XL, de Jia A, Yan ZX. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol. 2011;148:96-101.
34. Ruiz-Nodar JM, Marin F, Roldan V, Valencia J, Manzano-Fernandez S, Caballero L, Hurtado JA, Sogorb F, Valdes M, Lip GY. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high has-bled bleeding risk score? Circ Cardiovasc Interv. 2012;5:459-66. An observational study showing that use of triple therapy with oral anticoagulants in those with high bleeding risk increased major bleeding, but the net clinical benefit was in favor of their use.
35. Dewilde W, Berg JT. Design and rationale of the WOEST trial: what is the optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary stenting (woest). Am Heart J. 2009;158:713-8.
36. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. New Engl J Med. 2010;363:930-42.
37. Steg PG, Mehta S, Jolly S, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Chrolavicius S, Rao SV, Granger CB, Pogue J, Laing S, Yusuf S. Fondaparinux with unfractionated heparin during revascularization in acute coronary syndromes (futura/oasis 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. Am Heart J. 2010;160:1029-34. 1034 e1021.
38. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y. A new strategy for discontinuation of dual antiplatelet therapy: The RESET trial (real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012 [epub ahead of print]
39. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience/promus versus cypher to reduce late loss after stenting (excellent) randomized, multicenter study. Circulation. 2012;125:505-13.